Amy C. Peterson is EVP, Chief Development Officer of CytomX Therapeutics, Inc.. Currently has a direct ownership of 58,433 shares of CTMX, which is worth approximately $78,884. The most recent transaction as insider was on Mar 16, 2023, when has been sold 4,257 shares (Common Stock) at a price of $1.98 per share, resulting in proceeds of $8,428. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 58.4K
0% 3M change
0% 12M change
Total Value Held $78,884

Amy C. Peterson Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 16 2023
SELL
Open market or private sale
$8,428 $1.98 p/Share
4,257 Reduced 6.79%
58,433 Common Stock
Jul 20 2022
SELL
Open market or private sale
$10,597 $1.42 p/Share
7,463 Reduced 10.64%
62,690 Common Stock
Jul 19 2022
BUY
Grant, award, or other acquisition
-
20,000 Added 22.18%
70,153 Common Stock
Feb 02 2022
BUY
Grant, award, or other acquisition
-
40,000 Added 46.29%
46,421 Common Stock
May 31 2021
BUY
Grant, award, or other acquisition
$20,219 $6.09 p/Share
3,320 Added 34.08%
6,421 Common Stock
Nov 30 2020
BUY
Grant, award, or other acquisition
$19,815 $6.39 p/Share
3,101 Added 50.0%
3,101 Common Stock

Also insider at

EXEL
EXELIXIS, INC. Healthcare
ACP

Amy C. Peterson

EVP, Chief Development Officer
South San Francisco, CA

Track Institutional and Insider Activities on CTMX

Follow CytomX Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CTMX shares.

Notify only if

Insider Trading

Get notified when an Cytom X Therapeutics, Inc. insider buys or sells CTMX shares.

Notify only if

News

Receive news related to CytomX Therapeutics, Inc.

Track Activities on CTMX